Kaloyan M. Tsanov

Kaloyan M. Tsanov

Auto-generated profile, based on publicly available information

Kaloyan M. Tsanov

Cancer Biology & Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SSSimon Schwörer
Simon Schwörer
FCFrancesco V. Cimino
Francesco V. Cimino
MRManon Ros
Manon Ros
KTKaloyan M. Tsanov
Kaloyan M. Tsanov
CNCharles Ng
Charles Ng
CTCraig B. Thompson
Craig B. Thompson
Cancer-associated fibroblasts (CAF) are a major cell type in the stroma of solid tumors and can exert both tumor-promoting and tumor-restraining functions. CAF heterogeneity is frequently observed in pancreatic ductal adenocarcinoma (PDAC), a tumor characterized by a dense and hypoxic stroma that features myofibroblastic CAFs (myCAF) and inflammatory CAFs (iCAF) that are thought to have opposing roles in tumor progression. While CAF heterogeneity can be driven in part by tumor cell–produced cytokines, other determinants shaping CAF identity and function are largely unknown. In vivo, we found that iCAFs displayed a hypoxic gene expression and biochemical profile and were enriched in hypoxic regions of PDAC tumors, while myCAFs were excluded from these regions. Hypoxia led fibroblasts to acquire an inflammatory gene expression signature and synergized with cancer cell–derived cytokines to promote an iCAF phenotype in a HIF1α-dependent fashion. Furthermore, HIF1α stabilization was sufficient to induce an iCAF phenotype in stromal cells introduced into PDAC organoid cocultures and to promote PDAC tumor growth. These findings indicate hypoxia-induced HIF1α as a regulator of CAF heterogeneity and promoter of tumor progression in PDAC. Significance: Hypoxia in the tumor microenvironment of pancreatic cancer potentiates the cytokine-induced inflammatory CAF phenotype and promotes tumor growth. See related commentary by Fuentes and Taniguchi, p. 1560

1 July 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
JLJosef Leibold
Josef Leibold
MRMarcus Ruscetti
Marcus Ruscetti
ZCZhen Cao
Zhen Cao
YHYu-Jui Ho
Yu-Jui Ho
TBTimour Baslan
Timour Baslan
SLScott W. Lowe
Scott W. Lowe
To study genetic factors influencing the progression and therapeutic responses of advanced prostate cancer, we developed a fast and flexible system that introduces genetic alterations relevant to human disease directly into the prostate glands of mice using tissue electroporation. These electroporation-based genetically engineered mouse models (EPO-GEMM) recapitulate features of traditional germline models and, by modeling genetic factors linked to late-stage human disease, can produce tumors that are metastatic and castration-resistant. A subset of tumors with Trp53 alterations acquired spontaneous WNT pathway alterations, which are also associated with metastatic prostate cancer in humans. Using the EPO-GEMM approach and an orthogonal organoid-based model, we show that WNT pathway activation drives metastatic disease that is sensitive to pharmacologic WNT pathway inhibition. Thus, by leveraging EPO-GEMMs, we reveal a functional role for WNT signaling in driving prostate cancer metastasis and validate the WNT pathway as therapeutic target in metastatic prostate cancer. Significance: Our understanding of the factors driving metastatic prostate cancer is limited by the paucity of models of late-stage disease. Here, we develop EPO-GEMMs of prostate cancer and use them to identify and validate the WNT pathway as an actionable driver of aggressive metastatic disease. This article is highlighted in the In This Issue feature, p. 890

25 September 2025 in Nature Cancer
Verified
Journal Article
Open access
PDF file
KTKaloyan M. Tsanov
Kaloyan M. Tsanov
FBFrancisco M. Barriga
Francisco M. Barriga
YHYu-Jui Ho
Yu-Jui Ho
DADirena Alonso-Curbelo
Direna Alonso-Curbelo
GLGeulah Livshits
Geulah Livshits
SLScott W. Lowe
Scott W. Lowe
The role of driver gene mutations in sustaining tumor growth at metastatic sites is poorly understood. SMAD4 inactivation is a paradigm of such mutations and a hallmark of pancreatic ductal adenocarcinoma (PDAC). To determine whether metastatic tumors are dependent on SMAD4 inactivation, we developed a mouse model of PDAC that enables spatiotemporal control of Smad4 expression. While Smad4 inactivation in the premalignant pancreas facilitated the formation of primary tumors, Smad4 reactivation in metastatic disease suppressed liver metastases but promoted lung metastases. These divergent effects were underpinned by organ-biased differences in the tumor cells’ chromatin state that emerged in the premalignant pancreas and were distinguished by the dominance of KLF4 versus RUNX1 transcription factors. Our results show how epigenetic states favored by the organ of residence can influence the output of driver mutations in metastatic tumors, which has implications for interpreting tumor genetics and therapeutically targeting metastatic disease.

18 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
KTKaloyan M. Tsanov
Kaloyan M. Tsanov
FBFrancisco M. Barriga
Francisco M. Barriga
YHYu-Jui Ho
Yu-Jui Ho
DADirena Alonso-Curbelo
Direna Alonso-Curbelo
GLGeulah Livshits
Geulah Livshits
SLScott W. Lowe
Scott W. Lowe
Driver gene mutations can increase the metastatic potential of the primary tumor 1–3 , but their role in sustaining tumor growth at metastatic sites is poorly understood. A paradigm of such mutations is inactivation of SMAD4 – a transcriptional effector of TGFβ signaling – which is a hallmark of multiple gastrointestinal malignancies 4,5 . SMAD4 inactivation mediates TGFβ’s remarkable anti-to pro-tumorigenic switch during cancer progression and can thus influence both tumor initiation and metastasis 6–14 . To determine whether metastatic tumors remain dependent on SMAD4 inactivation, we developed a mouse model of pancreatic ductal adenocarcinoma (PDAC) that enables Smad4 depletion in the pre-malignant pancreas and subsequent Smad4 reactivation in established metastases. As expected, Smad4 inactivation facilitated the formation of primary tumors that eventually colonized the liver and lungs. By contrast, Smad4 reactivation in metastatic disease had strikingly opposite effects depending on the tumor’s organ of residence: suppression of liver metastases and promotion of lung metastases. Integrative multiomic analysis revealed organ-specific differences in the tumor cells’ epigenomic state, whereby the liver and lungs harbored chromatin programs respectively dominated by the KLF and RUNX developmental transcription factors, with Klf4 depletion being sufficient to reverse Smad4 ’s tumor-suppressive activity in liver metastases. Our results show how epigenetic states favored by the organ of residence can influence the function of driver genes in metastatic tumors. This organ-specific gene–chromatin interplay invites consideration of anatomical site in the interpretation of tumor genetics, with implications for the therapeutic targeting of metastatic disease.

15 May 2023
Verified
Other
Open access
SSSimon Schwörer
Simon Schwörer
FCFrancesco V. Cimino
Francesco V. Cimino
MRManon Ros
Manon Ros
KTKaloyan M. Tsanov
Kaloyan M. Tsanov
CNCharles Ng
Charles Ng
CTCraig B. Thompson
Craig B. Thompson
Cancer-associated fibroblasts (CAF) are a major cell type in the stroma of solid tumors and can exert both tumor-promoting and tumor-restraining functions. CAF heterogeneity is frequently observed in pancreatic ductal adenocarcinoma (PDAC), a tumor characterized by a dense and hypoxic stroma that features myofibroblastic CAFs (myCAF) and inflammatory CAFs (iCAF) that are thought to have opposing roles in tumor progression. While CAF heterogeneity can be driven in part by tumor cell–produced cytokines, other determinants shaping CAF identity and function are largely unknown. In vivo, we found that iCAFs displayed a hypoxic gene expression and biochemical profile and were enriched in hypoxic regions of PDAC tumors, while myCAFs were excluded from these regions. Hypoxia led fibroblasts to acquire an inflammatory gene expression signature and synergized with cancer cell–derived cytokines to promote an iCAF phenotype in a HIF1α-dependent fashion. Furthermore, HIF1α stabilization was sufficient to induce an iCAF phenotype in stromal cells introduced into PDAC organoid cocultures and to promote PDAC tumor growth. These findings indicate hypoxia-induced HIF1α as a regulator of CAF heterogeneity and promoter of tumor progression in PDAC.Significance:Hypoxia in the tumor microenvironment of pancreatic cancer potentiates the cytokine-induced inflammatory CAF phenotype and promotes tumor growth.See related commentary by Fuentes and Taniguchi, p. 1560

24 November 2025
Verified
Other
Open access
SSSimon Schwörer
Simon Schwörer
FCFrancesco V. Cimino
Francesco V. Cimino
MRManon Ros
Manon Ros
KTKaloyan M. Tsanov
Kaloyan M. Tsanov
CNCharles Ng
Charles Ng
CTCraig B. Thompson
Craig B. Thompson
Supplementary Figure 1, related to Figure 1